Evaluation of EPI/HIS in Healthy Volunteers: A Phase I Study

The primary objective of the EPI/HIS-trial is not explicitly stated. The study involves **healthy volunteers**, indicating that it may focus on evaluating physiological or pharmacological responses in a non-diseased population. The clinical relevance of such studies often lies in establishing baseline data or assessing the safety and tolerability of interventions in individuals without underlying medical conditions. There are no secondary objectives provided for this trial.

The clinical trial involves **healthy volunteers** with no underlying medical conditions. The study population includes both male and female participants, with an age range that corresponds to adults. The total number of participants has not been disclosed by the sponsor. The trial population was selected to exclude vulnerable groups, ensuring a focus on individuals with a general good health status. Lifestyle considerations such as diet, physical activity, and habits have not been specified. The study does not target any specific medical condition, as it is designed to assess outcomes in a healthy cohort.

The clinical trial is designed as a **Phase 3** study involving healthy volunteers, with no underlying medical conditions being targeted. The trial is set to commence recruitment on June 2, 2024, and is anticipated to conclude by June 2, 2027. The study employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. Participants will be randomly assigned to either the intervention group or the control group, with neither the participants nor the investigators aware of the group assignments, thus maintaining the integrity of the blinding process.

The sequence of study visits begins with an inclusion visit, which serves as a screening to confirm eligibility based on predefined criteria. Following successful inclusion, participants will undergo a series of follow-up visits at specified intervals to monitor their health status and collect necessary data. These visits are crucial for assessing the primary and secondary endpoints of the trial. The end-of-study visit marks the final assessment, where comprehensive evaluations are conducted to gather conclusive data on the study's outcomes.

Participant involvement is expected to last for the entire duration of the trial, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's methodology and design are structured to ensure the collection of high-quality data while prioritizing the safety and well-being of the participants throughout the study period.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the source data, further details about the **experimental medication** and any **non-experimental treatments** cannot be provided. The trial documentation should be consulted for comprehensive information regarding the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on June 2, 2024, with an estimated completion date of June 2, 2027. The efficacy assessment will be conducted through a series of pre-defined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The efficacy evaluation will be integral to determining the therapeutic impact of the investigational product under study. The trial's design and execution will adhere to rigorous scientific standards to ensure the reliability and validity of the efficacy outcomes.